fda warning compounded semaglutide safety 2024 2025 alerts health care providers, compounders and patients of dosing errors associated with injectable products Compounded "semaglutide" is not FDA-approved

Clinicians should consider prioritising review for people with type 2 diabetes on the affected GLP-1 RA preparation where: HbA1c greater than 86mmol/mol in the previous 3 to 6 months HbA1c greater than 86mmol/mol prior to starting the GLP1-RA HbA1c not recorded in the previous 6 months Urine albumin creatinine ratio (uACR) greater than 30mg/mmol Self-monitoring glucose readings (or Continuous Glucose Monitoring, where available) are persistently above individualised target range

(FDA, Food and Drug Administration) (EMA, European Medicines Agency) 2 7 1 ( , , , , , )

Some products featured on this website may be classified as research-use only and are not for human consumption

Microvascular dysfunction plays a central role in nerve injury